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Abstract
The incidence of oropharyngeal cancer and oral cancer is growing worldwide, both in young non-smokers and in 
young non-drinkers (smoking and drinking are considered the main risk factors). Epidemiologic studies suggest 
a strong association between the infection by human papillomavirus (HPV), especially types 16 and 18 (high on-
cological risk) which have already demonstrated their etiological role in anal tumours as well as in cervix cancer. 
There is clear epidemiologic evidence that both types of tumours relate to changes in sexual behaviour and that 
both are linked to sexual transmission of HPV. The number of oral and oropharyngeal cancer cases is rising nowa-
days, especially among young individuals with no typical toxic habits, such as tobacco and/or alcohol.
In this review we set out to update the aspects related to the onset of oral cancer, its relationship with HPV infec-
tion and whether this association may be due to the sexual transmission of the virus.
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Introduction
Head and neck carcinomas (HNCs) stem from the 
mucosa lining the oral cavity, the oropharynx, the hy-
popharynx, the larynx, the nasopharynx and the sino-
nasal tract. The most common histological type is squa-
mous cell carcinoma (SCC) (1,2).
Over 650,000 patients are diagnosed with head and 
neck squamous cell carcinoma (HNSCC) worldwide 
every year and over 350,000 die of it (3). In the USA, 
the incidence of HNSCC in pharynx and oral cavity is 
11.9 per 100,000, with men affected in a 3:1 proportion 
compared to women (4); furthermore, the incidence of 
oropharyngeal carcinoma has stepped up, specifically 
in the amygdala and in the base of the tongue, and in 
individuals aged 40-55 (4).
The similarities in the clinical aspects between the oral 
and genital injuries associated with HPV led clinicians 
in the eighties to suggest that HPV might be involved 
in oral carcinogenesis (3). Some of the factors involved 
would be HPV’s affinity to epithelial cells, HPV’s onco-
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genic potential and morphological similarities between 
genital and oropharyngeal epithelia (2). Up until now 
HPV’s role in HNSCC has been highly controversial, 
though, chiefly because the widely varying detection 
rates of the virus’ DNA (from 1% to 100%, depending 
on the detection method applied) (5). Other possible rea-
sons for confusion may have been regarding HNSCC 
as a single entity, or studies failing to specify whether 
the localization was just oral, oropharyngeal or others, 
which would render it difficult to extrapolate the ob-
tained data (2,3).
Recently, data from case-control and meta-analytic 
studies show that HPV would be, indeed, an independ-
ent risk factor for the development of oropharyngeal 
and oral carcinomas (3,6-8). HNSCCs associated with 
HPV seem to be, thus, a distinct clinical entity with a 
different evolution too, since these tumours have a bet-
ter prognosis than the HPV-negative ones (1,8). 
Moreover, a strong association seems to exist between pa-
tient age and HPV-16’s infection prevalence (9). These cas-
es occur mostly in white and Asian males (2) with no pre-
vious record of tobacco or alcohol consumption, two risk 
factors traditionally associated with this infection (1,3).
The association between these oncogenic HPV types 
(16 and 18) in cervix cancer as well as with anal cancer 
has been clearly demonstrated, just like the role of cer-
tain sexual conducts in their transmission (10). In this 
sense, evidence is starting to exist suggesting that cer-
tain sexual practices, such as oral sex (oral-genital con-
tact) and others (oral-anal contact), and certain sexual 
conducts (such as having many sexual partners) would 
favour the virus to reach the oral cavity and be in a posi-
tion to play a role in the development of neoplasia in the 
oropharyngeal region (11).
Material and Methods
In order to carry out this review, a search has been con-
ducted for articles from 2000 up to 2010 related to HN-
SCC, especially at orpharyngeal and OSCC levels, using 
keywords such as “head and neck squamous cell can-
cer”; “HPV” or “oral cancer”. Articles related to HPV 
and larynx cancer have been excluded, as they exceed 
this field. For our purposes, data bases such as Medline, 
Pubmed, Current Contents Connect, Cochrane plus 
and Catálogo Cisne have been used.
Results
-Relationship among HPV infection, oral cancer and 
oropharyngeal cancer. The role of sexual conducts.
Tobacco, alcohol, poor oral hygiene and genetics remain 
important risk factors in head and neck tumour’s global 
figures (for individuals aged over 60), although HPV is 
currently acknowledged as one of the primary causes be-
hind the rise in oropharyngeal cancer cases. In the USA, 
between 40% and 80% of oropharyngeal cancers are 
caused by HPV, while in Europe figures vary from Swe-
den’s 90% to less than 20% found in other communities 
with a higher prevalence of tobacco consumption (1).
HNC’s total incidence in the USA has diminished over 
the last years due to a lower consumption of tobacco. 
Yet the incidence of HPV related oropharyngeal can-
cer seems to be rising, as shown by SEER (Surveillance 
Epidemiology and End Results), not only in the USA but 
also in Sweden, highlighting the relevance of this causal 
association (1). SEER’s data show a statistically signifi-
cant growth of oropharyngeal cancer affecting young 
adults aged between 20 and 44 (12).
As for OSCC, Miller et al. (7) performed a study evalu-
ating the likelihood of finding high oncogenic risk HPV 
types in patients with OSCC injuries. They found a 
higher detection prevalence of HPV’s viral DNA in cell 
samples coming from neoplasias, verrucous carcinomas 
and OSCC than in healthy mucosa. The probability of 
finding some high oncological risk types (HPV 16 and 
18) was 2.8 times higher, suggesting that these viral 
types are a significant risk factor in the development of 
OSCC injuries (7).
Termine et al. (2), in a meta-analytical review of HN-
SCC cases (oral and others) and of diverse HPV detec-
tion techniques concluded that variations in viral DNA 
prevalence may be affected by the failure to distinguish 
the tumour’s localization as well as by the detection 
technique employed (PCR or in-situ hybridization) (2).
Even though it has been known for a long time that HPV 
is a key etiological factor in anogenital cancer, it is only 
recently that its etiological relationship with an HNSCC 
subtype has been proved. There are over 100 different 
types of HPVs, and at least 15 of these have oncogenic 
potential. Notwithstanding, most HNSCCs (>90%) are 
caused by the HPV-16 type, the same type involved in 
anogenital cancers associated with HPV (1).
On the other hand, HPV prevalence seems lower in 
OSCC injuries than in oropharyngeal carcinomas (6). 
The HPV prevalence difference between OSCC cases 
and oropharyngeal carcinoma in consumers and non-
consumers of tobacco and/or alcohol would support the 
theory stating that these tumours might constitute an 
etiologically different subgroup within head and neck 
tumours (13-16).
HPV genital infection is the most common sexually 
transmitted infection (STI) these days, with an inci-
dence of about 5.5 million worldwide. About 75% of 
sexually active men and women have been exposed to 
HPV at some point in their lives (17). HPV types 16 and 
18 are responsible for about 70% of cervix, vagina and 
anal cancers and for about 30% to 40% of vulva, penis 
and oropharyngeal cancer cases (10,18).
The likely ethiological role of HPV in cancer has been 
put forward after finding out that the sexual partner of 
patients diagnosed with an HPV infection presented a 
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higher risk of developing a head and neck cancer (19). 
However, between 10% and 30% of HPV-positive HN-
SCCs occur among heavy smokers and/or drinkers, 
which makes it harder to clearly establish the true etio-
logical role that HPV may play (8).
As has already been said, HPV infection is a STI and 
the consulted studies suggest that the number of sexual 
partners in the lifetime would be an important risk fac-
tor, not only for anal and cervix cancer, but also for the 
development of HNSCC (19). In case-control studies, 
the risk of developing HPV induced HNSCC doubled in 
individuals who reported having had between one and 
five sexual partners and increased five times in those 
who reported having had six or more, compared to those 
who did not practice oral sex (8,20). 
A recent study suggests a rise in HPV infection inci-
dence in young adults, mainly due to an earlier initia-
tion of sex and to a higher number of sex partners (19). 
In the USA, most school age youngsters report having 
had oral sex, over two thirds of them with more than 
one partner, which would be facilitating the exposure of 
HPV to the oropharyngeal epithelium (9).
Yet it is also important to add that HPV-positive HNSCC 
cases were present in individuals who had had less sexual 
partners. Thus, over 50% of patients with HPV-positive 
tumours reported having had five or less sexual partners 
while between 8% and 40% reported having never had 
oral sex. Therefore, even though sexual conducts seem 
to be a key risk factor for HPV-positive HNSCC, the ab-
sence of a high number of sexual partners does not pre-
vent the development of an HPV-positive HNSCC (1).
Both men and women can be asymptomatic HPV carri-
ers and the virus transmission to the oral cavity would 
mainly happen through unprotected sex practices. Re-
search carried out by D’Souza et al. (19) shows an HPV 
increase in couples who practiced oral sex (19,20). On the 
other hand, individuals who have previously had HPV 
infections are thirty two times more likely to develop 
malignant injuries than those who have not (20,21). 
A thorough study published in 2010 about sexual behaviour 
and HNC risk carried out by INHANCE (International 
Head and Neck Cancer Epidemiology Consortium), shows 
that sexual behaviour is linked to the risk of developing 
an HPV associated cancer, depending on its localization. 
Thus, the study found out that oropharyngeal cancer was 
significantly associated with having had six or more sex 
partners and four or more oral sex partners (22).
As for amygdala cancer, it was associated with having 
had four or more oral sex partners; and among men, to 
having ever had oral sex and to a younger age at the 
time of their first sexual relationship. As far as tongue 
base cancer is concerned, it was linked, among women 
to having had oral sex at least with two partners; among 
men, to having had sex with other men. Little evidence 
was found, though, of association between the analysed 
sexual behaviours and their relationship with larynx 
and oral cavity cancer (22).
D’Souza et al. (19) found that a history of numerous 
sexual partners (twenty six or more) was significantly 
associated with the presence of oropharyngeal cancer. 
The same happened when oral sex had been practiced 
with more than six individuals (18-20). This link was 
even stronger among individuals with HPV-16 oral in-
fection, regardless their tobacco or alcohol consumption 
(19). HPV oral infection was more strongly related to 
the number of recent couples who had practiced oral sex 
than to couples who reported having only had vaginal 
sex (20,23).  
It has also been proved that the prevalence of oral infec-
tion caused by high oncological risk HPV is higher in 
seropositive individuals and that it increases with age, 
male gender and infection by VHS-2 (24).
HIV-positive individuals also have a higher likelihood 
of developing an oral infection caused by HPV, of being 
infected by more than one type of HPV and of HPV be-
ing of high oncogenic risk (18). The risk of infection by 
high oncogenic risk HPV among HIV-positive individ-
uals was thirteen times higher in those who practiced 
oral sex with more than one person during the previous 
year (22,24). This might indicate that HPV co-infection 
with other pathogens would increase the infectivity and 
transmissibility of both (24).
Lastly, some authors disagree and consider the possibil-
ity of HPV infection in HSNCC patients being just a 
temporal non-causative infection. Acha-Sagredo et al. 
(25) did not find HPV’s DNA in forty seven patients al-
ready treated of OSCC (25).
In this sense, Herrero et al. (10) suggested too that HPV 
infection is a temporal one, furthermore related to the 
presence of a malignant or pre-malignant injury and that 
it should be born in mind that the detection of HPV’s 
DNA in tumours should not necessarily have to indi-
cate, per se, a causal association (10,16). Despite these 
data, studies confirming the high frequency of HPV’s 
DNA detection in HNSCC are far more numerous (5).  
-Pathogenic mechanism of oral/oropharyngeal cancer 
onset in relation with HPV
Human Papillomavirus (HPV) belongs to the Papil-
lomaviridae family. The most important ones (of high 
oncogenic risk) are types 16 and 18 (8,26). Infections 
by to the high risk types manifest a silent clinic, cause 
infections and, in a lower proportion, lead to high grade 
squamous intra-epithelial injuries and cancer (10,26). 
The cycle starts when viral DNA builds into keratino-
cytes’ cell genome (2). For a malignant transformation 
caused by VPH to occur, viral DNA has to penetrate 
the epithelial cells of the guest in first place. Then the 
synthesis of E6 and E7 viral proteins takes place due 
to the disruption of E2 (viral protein). E6 viral protein 
inactivates p53, on the one hand, and E7 oncoprotein 
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would inactivate the pRb (both are tumour suppressor 
proteins), producing an increment of the mitotic ac-
tivity of the affected cell (5,16). All that would lead to 
genomic instability, to an absence of DNA reparation, 
to defects in apoptosis and in the regulation of the cell 
cycle. HPV might contribute both to oncogenesis and to 
tumour progression. As a result, it would not only be re-
quired to suffer from a HPV infection, but both certain 
mutations in the suppressor genes and the activation of 
oncogenes caused by the virus must occur, or otherwise 
have a special genetic susceptibility, for a neoplastic 
epithelial injury to develop (3,13,16,27).
When an HPV infection happens, antibodies such as 
HPV-16 L1 as well as HPV-16 E6 and E7 viral proteins 
show up in serum. These viral proteins are capable of 
producing a malignant transformation of upper respira-
tory, anal and genital tracts cells. The risk of develop-
ing OSCC when having antibodies against these pro-
teins would be between 1.5 and 3.4 times higher, for the 
oral cavity, and between 3.5 and 19 times higher, for the 
oropharynx, than otherwise (10,26).
P16 is another protein involved in cell cycle used by 
many authors as a likely marker for oral cancer associat-
ed with an HPV infection. It has been found out that an 
over-expression of P16 would be linked to HPV-positive 
oropharyngeal carcinomas, poorly differentiated and in 
locally more advanced stages (T4, N2-3) (16). Hence, 
in HPV-positive malignant injuries the augmented ex-
pression of this protein could be used as a favourable 
prognosis marker (16,28). On the other hand, the loss 
of the P16 expression by deletion, hypermethylation or 
mutation is common in OSCCs caused by alcohol and 
tobacco, producing injuries with a worse prognosis as 
they do not respond to chemotherapy or radiotherapy in 
the same way. E6 HPV’s oncoprotein can inactivate P53 
too, although in these cases it would be a functional in-
activation, not a mutation as it happens in OSCCs asso-
ciated with tobacco and alcohol intake. In fact, the rate 
of P53 mutations due to HPV is very low (4,16,28,29).
All this would support the existing evidence of oral/
oropharyngeal cancer etiologically associated with 
HPV having an increased survival and a better prog-
nostic, as both an over-expression of P16 and very low 
P53 mutation rates would happen, and all this might be 
linked to infected cells being more sensitive to current 
radiotherapy and chemotherapy (28,29). Table 1 shows 
the differences between HPV-positive and HPV-nega-
tive oral cancer. 
Table 1. Differences between oropharyngeal cancer HPV + and HPV -.
HPV-positives HPV-negatives
Age Younger individuals (30-50) Older individuals (50-70)
Risk factor
Oral sex, French kiss, high number of sexual 
partners, history of STI
Long history of tobacco and/or alcohol 
consumption
Incidence Increasing Decreasing
Localization Tongue base, amygdalae Oral mucosa
Field cancerization No Yes
Histology Poorly differentiated - basaloid Clearly differentiated
Stage at diagnosis T3-4; N2-3 Variable
Biomarkers
Over-expressed P16;         Inactivation of P16 
and pRb
Loss of P16; P53 and pRb mutation; 
cyclin-D1, EGFR and survivine over-
expression
Chromosomal mutations Less frequent Frequent
Prognosis
Very good, increased sensitivity to radiothe-
rapy and chemotherapy
Poor
Distant metastasis Rare Frequent
Second primaries Rare Frequent
Five year survival rate 60%-90% 20%-70%
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-Treatment of oral/oropharyngeal cancer associated 
with HPV. The odontologist’s  role in its early preven-
tion and detection.
The average time span from the moment in which HPV 
infection occurs to the onset of cancer has been esti-
mated as around twelve years, so according to some 
authors the number of young adults who will develop 
oropharyngeal cancer is expected to increase over the 
coming years (30,31).
In line with what has been expressed in the previous 
section, several authors agree in pointing out that pa-
tients who display small size tumours, over-expression 
of P16 and high HPV viral charge in the tumour sample, 
have an increased survival in spite of the presence of 
lymphatic nodules (9,16,28).
Nguyen et al. (9) suggest that patients who satisfy these 
requirements could be included in some study protocol 
in order to be treated with radiotherapy only, aiming at 
reducing the treatment’s morbidity as well as increasing 
their quality of life.    
This modality should be considered experimental, since 
surgery plus post-operative chemotherapy or radiother-
apy remains the treatment of choice in patients with lo-
cally advanced HNC (9).
HPV vaccine is the first explicitly designed to prevent vi-
rus induced cancer (23,31). HPVs 16 and 18 are the main 
targets of the currently approved vaccines and the avail-
able data confirm the success in the incidence reduction of 
pre-cancerous cervical injuries for these types (31-33). The 
vaccine’s efficacy is limited by two factors since not all 
cancers are caused by HPVs 16 and 18; and there seems to 
be a requirement of vaccinating young women before they 
get infected by these two types (31). To be effective, such 
vaccination should start before “sexual puberty” as adoles-
cents regard oral sex as a safe option to prevent non wanted 
pregnancies and other STIs (including HIV) (33).
There are two commercially available prophylactic vac-
cines against HPV today: the bivalent (VPHs 16 and 18) 
Cervarix® (GSK) and the tetravalent (VPHs 6,11,16 and 
18) Gardasil® (Merck).  Theoretically, there is no rea-
son for these vaccines to fail to work against these same 
viruses in different localizations (such as oral cavity, 
pharynx, larynx or the anogenital region). Proving that 
the vaccine also prevents oropharyngeal cancer would 
mean not only a landmark in the prevention of these 
diseases, but it would also provide the missing link in 
the chain of evidences with the ultimate proof of HPV 
induced viral etiology of these tumours (3,33).
Vaccination is approved in females aged 9 to 26. The 
vaccination primary target population should be fe-
males aged 11 and 12. However the vaccine can also be 
administered to females up to 9 years old and to those 
aged between 13 and 26 who have been sexually active. 
There are no available data about the vaccine’s efficacy 
in individuals aged over 26 (15,17,34).
Clinicians, including professionals involved in oral health 
should pay attention to the risk of oropharyngeal cancer 
in young individuals, who neither smoke nor drink, to 
avoid an unnecessary diagnostic and therapeutic delay. 
There seems justified, considering all that has been said 
so far in this paper, the inclusion of questions over sexual 
practices in the anamnesis of young patients presenting 
enlarged lymphatic nodules and/or masses in amygdalae 
and/or sore throat, to rule out a possible underlying HPV 
associated neoplasia. According to some authors, an early 
referral to the specialist would reduce morbidity as well 
as the cost of the treatment (9). Routine exploration of 
mucous, tongue, and neck palpation ought to be manda-
tory practices in any oral exploration in order to perform 
the detection of any potentially malignant injury (35).
So far, recommendations on early detection of oral can-
cer focused on patient groups who traditionally had a 
higher risk of developing it, i.e. individuals aged over 
60, tobacco and/or alcohol consumers as well as indi-
viduals with certain hereditary diseases, such as Fanco-
ni’s anaemia, or with a past history of oral cancer (35).
Brondani, in his editorial published in an Odontology ref-
erence review, also wonders what our patients know about 
HPV, about oral sex and about oral cancer. Even more, he 
acknowledges that dentists have not been properly educated 
in these aspects, so he encourages a more detailed study of 
these subjects, their registration in the patient’s clinic history 
and to supply information about them to patients (21). 
Scientific evidence in this point seems to indicate that 
we must be educated, and educate our children, on other 
potential risk factors in the onset of oral cancer, such as 
non-protected oral sex, and not only about tobacco and/
or alcohol consumption, especially to early detect this 
injuries in adolescents and young adults or, better yet, 
to try to prevent them (21). 
Conclusion
Patients with HPV associated HNSCC are younger and 
present reduced tobacco and/or alcohol intakes. There 
are certain molecular profiles of HPV-positive HNSCCs 
that differentiate them from HPV-negative cancers, as 
a result they could be considered a biological entity 
separated from the rest of HSNCC, and of likely sexual 
transmission. According to the current literature re-
vised, risk factors associated with this HNSCC variant 
are similar to those of cervix cancer, including number 
of sexual partners, younger age at their first sexual inter-
course, oral sex practices, a history of genital warts and 
younger age. Dentists, as health professionals, ought to 
get more heavily involved in the detection of these fac-
tors implied in the etiology and pathogenesis of these 
injuries in order to contribute to the early detection and 
prevention of this kind of injuries, especially in young 
patients with no risky habits traditionally linked to oral 
cancer, such as tobacco and/or alcohol consumption.
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